NCT02644252

Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer

Tocotrienol as a Nutritional Supplement in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 79 (actual)
• Sponsor: Vejle Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

There is a need for improving the effect of first-line chemotherapy for lung cancer patients, preferably by using an approach with none or very few side effects. In this trial the investigators incorporate δ-tocotrienol/placebo as a nutritional supplement on top of standard chemotherapy for patients with advanced non-small cell lung cancer.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	Day 1: Cisplatin 75 mg/m2
DRUG	Day 1: Vinorelbine 25 mg/m2
DRUG	Day 8: Capsule vinorelbine 50 mg/m2
DRUG	Day 1: Carboplatin AUC=5
DRUG	Day 1: Vinorelbine 30 mg/m2
DRUG	Day 8: Capsule vinorelbine 60 mg/m2
DIETARY_SUPPLEMENT	Tocotrienol 300 mg x 3 daily until progression
DRUG	Placebo 1 capsule x 3 daily until progression

Timeline

• Start date: 2016-01-01
• Primary completion: 2019-05-09
• Completion: 2021-01-15
• First posted: 2015-12-31
• Last updated: 2021-05-03

Locations

1 site across 1 country: Denmark